Bibliography
- Hohnloser SH, Crijns HJJ, van Eickels M, Effect of Dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668–78
- Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429
- Food and Drug Administration. FDA Drug Safety Communication: severe liver injury associated with the use of Dronedarone (marketed as Multaq). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm [Accessed August 23 2012]
- Food and Drug Administration. Labeling revision: highlights of prescribing information (Multaq). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022425s002lbl.pdf [Accessed August 23 2012]
- Connolly SJ, Camm AJ, Halperin JL, Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–76
- European Medicines Agency. European Medicines Agency recommends restricting use of Multaq. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&mid=WC0b01ac058004d5c1 [Accessed August 23 2012]
- De Ferrari GM, Dusi V. Drug safety evaluation of Dronedarone in atrial fibrillation. Expert Opin Drug Safe 2012;11(6):1023–45
- Brundel BJ, Van Gelder IC, Henning RH, Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol 2001;37:926–32
- Chatterjee S, Ghosh J, Lichstein E, Meta-analysis of cardiovascular outcomes with Dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110:607–13
- Chiang CE, Naditch-Brûlé L, Murin J, Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–9
- Parvez B, Vaglio J, Rowan S, Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:539–45
- European Medicine Agency: assessment report for MULTAQ. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001043/WC500121610.pdf [Accessed August 23 2012]
- Akerborg O, Nilsson J, Bascle S, Cost-effectiveness of Dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther 2012;34:1788–802
- Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther 2012;340:161–8
- Mullard A. Second chance for Dronedarone after recent setback? Lancet 2012;379:601